Breaking News

Roche Names R&D Head

January 15, 2013

Reed joins executive committee

John C. Reed, M.D., Ph.D., has been appointed head of Roche Pharma Research and Early Development (pRED) and member of the corporate executive committee, effective April 2, 2013. He will be based in Basel, reporting to Severin Schwan, chief executive officer of the Roche Group. 
 
Prior to joining the company, he was chief executive officer at Sanford-Burnham Medical Research Institute in La Jolla, CA. He is a leading biomedical researcher with a focus on cancer, neuroprotection, autoimmunity, and other diseases. Dr. Reed has authored several hundred medical research publications and is among the world’s most highly cited scientists for his research contributions. 
 
Mr. Schwan said, “We are delighted to welcome John Reed to Roche, who has led one of the world’s top laboratory-based medical research institutes. With his broad scientific and medical background he is ideally positioned to drive Roche’s strategy of translating a better understanding of disease mechanisms into promising therapeutics.”
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus